IGFBP2 and Global developmental delay: These findings, if replicated, may help prognosis and in counseling families identified with a 15q11.2 BP1-BP2 microdeletion to further expand the clinical phenotype of this emerging syndrome, now recognized as the most common cytogenetic finding in those presenting with ASD with or without congenital anomalies and developmental delays.